Pericardial fluids or Cardiopulmonary Bypass-Is There a Major Culprit for Changes in Coagulation and Inflammation?


Journal

The Thoracic and cardiovascular surgeon
ISSN: 1439-1902
Titre abrégé: Thorac Cardiovasc Surg
Pays: Germany
ID NLM: 7903387

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 7 2 2019
medline: 22 9 2020
entrez: 7 2 2019
Statut: ppublish

Résumé

From the results of a previous study, it remained to be investigated if a perioperative rise of few tested coagulation and inflammation markers is caused by conventional cardiopulmonary bypass (CPB) itself or rather by direct recirculation of pericardial fluids. Forty-eight patients operated on with conventional CPB for myocardial revascularization were randomized either for direct recirculation of pericardial suction fluids or for cell saving (CS). Thrombin-antithrombin complexes showed lower values intraoperatively in the CS group ( Direct recirculation of pericardial fluids rather than conventional CPB itself causes major intraoperative changes of some coagulation markers. Pericardial blood loss with direct recirculation should be kept to a minimum to avoid unnecessary activation of coagulation. Inflammation markers need further investigations.

Sections du résumé

BACKGROUND
From the results of a previous study, it remained to be investigated if a perioperative rise of few tested coagulation and inflammation markers is caused by conventional cardiopulmonary bypass (CPB) itself or rather by direct recirculation of pericardial fluids.
METHODS
Forty-eight patients operated on with conventional CPB for myocardial revascularization were randomized either for direct recirculation of pericardial suction fluids or for cell saving (CS).
RESULTS
Thrombin-antithrombin complexes showed lower values intraoperatively in the CS group (
CONCLUSION
Direct recirculation of pericardial fluids rather than conventional CPB itself causes major intraoperative changes of some coagulation markers. Pericardial blood loss with direct recirculation should be kept to a minimum to avoid unnecessary activation of coagulation. Inflammation markers need further investigations.

Identifiants

pubmed: 30727012
doi: 10.1055/s-0039-1677836
doi:

Substances chimiques

Biomarkers 0
Fibrin Fibrinogen Degradation Products 0
Inflammation Mediators 0
antithrombin III-protease complex 0
fibrin fragment D 0
Antithrombin III 9000-94-6
Peptide Hydrolases EC 3.4.-

Types de publication

Comparative Study Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-222

Informations de copyright

Georg Thieme Verlag KG Stuttgart · New York.

Déclaration de conflit d'intérêts

The authors have no disclosure or conflict of interest.

Auteurs

Hagen Gorki (H)

Herz-, Thorax- und Gefäßchirurgie, Universitätsklinik Ulm, Ulm, Germany.

Julia Nakamura (J)

Herz-, Thorax- und Gefäßchirurgie, Universitätsklinik Ulm, Ulm, Germany.

Andreas Kunert (A)

Herz-, Thorax- und Gefäßchirurgie, Universitätsklinik Ulm, Ulm, Germany.

Markus Hoenicka (M)

Herz-, Thorax- und Gefäßchirurgie, Universitätsklinik Ulm, Ulm, Germany.

Andreas Liebold (A)

Herz-, Thorax- und Gefäßchirurgie, Universitätsklinik Ulm, Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH